

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on June 10, 2003, 2003.

Frank C. Eisenschink
Frank C. Eisenschink, Ph.D., Patent Attorney

FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1614
Patent Application
Docket No. UF-260XCI
Serial No. 09/997,447

#11
JPL
6/17/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : William R. Jarvis
Art Unit : 1614
Applicant(s) : Nathan Andrew Shapira, Mary Catherine Lessig, Daniel John Driscoll
Serial No. : 09/997,447
Filed : November 30, 2001
Conf. No. : 3440
For : Treatments for Neurogenetic Disorders, Impulse Control Disorders, and Wound Healing

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited document is also attached.

It is respectfully requested that the Examiner indicate consideration of the cited reference by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/dkt

Attachments: Form PTO/SB/08 (1 page)
Copy of cited reference